Coherus Oncology (CHRS): Why Analysts See +845% Upside to $7.75

Key Takeaways

• The central target of $7.75 is the arithmetic mean of four verified analyst price targets, which range from a low of $4.00 to a high of $10.00.
• At a recent price near $0.82, reaching $7.75 would require upside of roughly 845% — a very large move that reflects the stock's deep decline rather than a modest gap.
• Bullish analysts point to LOQTORZI's commercial momentum, a leaner cost structure, and a pipeline of tagmokitug and casdozokitug with multiple data readouts expected.
• The biggest risks are heavy cash burn, an unstable revenue base, and dependence on early-stage clinical data and additional financing.
• The wide $4.00-to-$10.00 range signals meaningful disagreement about how the company's pipeline and commercial growth should be valued.

Analyst Price Targets and Consensus View

The $7.75 central target is the arithmetic mean of four current analyst price targets with identifiable firms and dates: H.C. Wainwright's Douglas Tsao initiated coverage with a Buy and a $7.00 target (October 29, 2026); Maxim Group's Jason McCarthy reiterated Buy with a $4.00 target (October 30, 2026); Guggenheim maintained Buy with a $10.00 target after lowering it from $12.00 (August 7, 2026); and Oppenheimer maintained Buy with a $10.00 target (August 6, 2026). TD Cowen maintains a Buy rating but does not publish a specific target. Those four figures average to $7.75, with a spread of $4.00 to $10.00. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The gap between the cautious Maxim view and the more aggressive Guggenheim and Oppenheimer targets reflects fundamentally different assumptions about how quickly LOQTORZI scales and whether the pipeline readouts translate into durable value.

Current Market Position and Path Toward the Target

CHRS has traded near $0.82 recently, toward the lower end of a 52-week range of roughly $0.73 to $2.62. Reaching $7.75 would require a move of approximately 845%, which is a very large gap even by the standards of small-cap biotech. LOQTORZI (toripalimab-tpzi), an anti-PD-1 therapy that is the only U.S.-approved treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC), is the commercial foundation. The pipeline includes tagmokitug, an anti-CCR8 antibody, and casdozokitug, an anti-IL-27 antibody, both in mid-stage trials. Financially, the company is not yet self-funding. LOQTORZI posted 2025 net revenue of about $40.8 million, up 113% year over year, and management guided 2026 revenue of $57–62 million, with a peak target of $150–200 million by 2028.

What Could Support a Move Toward the Target

Several factors underpin the bullish targets. LOQTORZI holds a differentiated position as the only preferred NCCN-recommended therapy for recurrent or metastatic NPC, giving it a defensible niche with limited direct competition. Six consecutive quarters of declining SG&A and a reduced headcount signal a structurally leaner operating model. The balance sheet was transformed after divesting the biosimilar franchise, with secured and convertible debt cut from roughly $480 million to about $38.8 million. Multiple clinical readouts for tagmokitug and casdozokitug across head and neck, colorectal, esophageal, and liver cancers, plus a Johnson & Johnson collaboration in prostate cancer, provide potential catalysts that could justify materially higher valuations.

What Could Prevent the Target From Being Reached

The principal obstacle is cash burn and execution risk. Trailing-twelve-month operating and free cash flow have been deeply negative, and revenue remains too small to cover core expenses. The stock has already declined sharply over the past year, reflecting dilution risk from the equity raises needed to fund operations. Clinical and regulatory outcomes are uncertain: early efficacy signals for tagmokitug and casdozokitug must mature into durable, registration-enabling data. A delay, a disappointing readout, or slower-than-expected LOQTORZI adoption could prompt analysts to revisit their revenue growth assumptions and lower targets, as Guggenheim did in trimming its target from $12 to $10.

Technical Levels and Market Structure

CHRS sits near the bottom of its 52-week range, with the $0.73 area representing the recent low and a meaningful support zone. The $1.00 mark is a psychological level that the stock has struggled to hold, while prior trading near $2.60 marks a significant overhead resistance area. The path to any higher target would require first reclaiming and holding the $1.00 level, then building through a series of prior highs. Given the stock's small float and market capitalization of roughly $129 million, price action can be volatile on relatively modest volume.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may use different periods and the specific horizon is not always disclosed. Investors should watch the next earnings report, LOQTORZI quarterly demand trends relative to the 10–15% guided growth, cash balance trajectory, and the timing of tagmokitug and casdozokitug data readouts. Any new financing, partnership, or regulatory milestone — and any analyst target revisions — are also directly relevant to whether the wide target range narrows.

Using AI Tools to Complement Research

In my own workflow, I have found Tickeron’s AI Daily Buy/Sell Signals helpful for layering real-time technical insights onto fundamental analysis. The platform monitors thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on shifting market conditions and AI-driven patterns, which can help identify when momentum may be changing around names like CHRS.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume